tag:blogger.com,1999:blog-28450497.post9058341307427534668..comments2009-10-22T06:43:08.304-04:00Adam J. Fein, Ph.D.http://www.blogger.com/profile/12217252282643255442noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-28450497.post-19346355303758367962009-10-22T06:42:54.254-04:002009-10-22T06:42:54.254-04:00They’re taking a lesson on what Express Scripts did relative to simvastatin a few years ago!Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-28450497.post-77828734545951323962009-10-21T10:26:53.034-04:002009-10-21T10:26:53.034-04:00I don&#39;t agree with the first comment above. The risks to Lilly are very high especially during the initial launch year. If anything, this reminds me of Express Scripts trying to get doctors to switch to Zocor in 2006 before it went generic. This definitely hurt Lipitor.<br /><br />I don&#39;t get your comment about PBMs wanting more expensive drugs. Maybe that was true in the past but you are absolutely correct that generics are what drives PBMs today.<br /><br />Thanks for pointing out this story because I missed it in the news.<br /><br />JBAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-28450497.post-58389229363238324602009-10-21T10:12:21.736-04:002009-10-21T10:12:21.736-04:00Adam,<br /><br />Come on! You know darn well that Lilly still has never gotten over their poor PBM experiences from many moons ago with their PCS purchase (Advance/PCS/Caremark).<br /><br />Medco is just rubbing it in.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-28450497.post-75228833185292594142009-10-21T09:09:13.889-04:002009-10-21T09:09:13.889-04:00Adam,<br /> As a fellow native of the City of Brotherly Love, Let&#39;s go Phillies!!George Hillhttp://www.leerink.comnoreply@blogger.comtag:blogger.com,1999:blog-28450497.post-42926551589991052132009-10-21T08:59:22.126-04:002009-10-21T08:59:22.126-04:00Adam, <br />Have you considered how this just might be a positive thing for Lilly! The hot topic out there right now is &quot;comparative effectiveness&quot; . At the same time Pharmaceutical companies are taking a lot of heat for ghost writing, transparency of payments to physicians, credibility issues with studies too closely tied to the manufacturer, etc The brand manufacturer gets several things out of this Medco announcement. Access to market, trial participants, physician participation, no direct link to the manufacturer. It is expected that 25% of participants will benefit from this drug, so the manufacturer has a large steak in this and prices are considerably higher. What if there is a rebate deal behind this too. The PBM created a win win scenario.Anonymousnoreply@blogger.com